久久婷婷国产综合精品,久久久久久久性潮,换脸国产av一区二区三区,韩国精品一区二区三区无码视频 ,久久久久成人精品无码

  • FDA Approves First Biosimilar for Non-Hodgkin’s Lymphoma americanpharmaceuticalreview
    November 29, 2018
    The U.S. Food and Drug Administration (FDA) approved Truxima (rituximab-abbs) as the first biosimilar to Rituxan (rituximab) for the treatment of adult patients with CD20-positive.....
  • Poteligeo approved in Europe for Mycosis Fungoides, Sézary Syndrome pharmatimes
    November 27, 2018
    Kyowa Hakko Kirin (Kyowa Kirin) has received marketing authorisation Europe for use of Poteligeo to treat Mycosis Fungoides and Sézary Syndrome, the two most common subtypes of cutaneous T-cell lymphoma, a rare type of non-Hodgkin’s lymphoma.

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194
+86 15021993094

PharmaSources Customer Service